Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acumen Pharmaceuticals Inc
NASDAQ ABOS
Data sourced from
and
and
Acumen Pharmaceuticals Inc Total Non-Current Liabilities 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 2,116.54%
Acumen Pharmaceuticals Inc Total Non-Current Liabilities 2 year CAGR is 2,116.54% for the Trailing 12 Months (TTM) ending March 31, 2024, a 2,507.81% change year over year. Total Non-Current Liabilities is the sum of long-term debt and other non-current liabilities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Acumen Pharmaceuticals Inc Total Non-Current Liabilities for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 829.00 K, a 1,237.10% change year over year.
-
Acumen Pharmaceuticals Inc Total Non-Current Liabilities for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 62.00 K, a -99.89% change year over year.
-
Acumen Pharmaceuticals Inc Total Non-Current Liabilities for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 56.65 M.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ABOS
| CEO | Mr. Daniel J. O'Connell M.B.A. |
| IPO Date | July 1, 2021 |
| Location | United States |
| Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email